Agoracom Blog

Ortho Regenerative Technologies $ $ORTIF Well-positioned for Next Phase of Development

Posted by AGORACOM at 3:43 PM on Tuesday, March 2nd, 2021

MONTREAL , March 2, 2021 – Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) (” Ortho RTI ” or the ” Company “), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today provided a review of 2020 calendar year activities and a look forward at planned future milestones as the Company transitions from preclinical to clinical stage.

2020 Achievements

  • Completed four non-brokered private placements that raised an aggregate C$6.7 million . The company now has more than $2 million cash on hand to fund its regulatory and clinical stage projects through 2022.
  • In March and July, Ortho RTI announced positive preclinical results that confirmed the safety profile and demonstrated statistically significant improvement over standard of care for rotator cuff repair.
  • Following a request for designation to the FDA, ORTHO-R was classified in August as a drug/biologic, which management believes will enhance its long-term market potential.
  • In October, the Company appointed Mukesh Ahuja , MBBS, MSc as Vice-President Clinical and Medical Affairs, who brings extensive expertise in orthobiologics clinical development.
  • In October, Ortho RTI shares began trading on the OTCQB market, facilitating better access for US investors and improved trading liquidity.
  • In November, Ortho RTI initiated the scale-up and manufacturing of cGMP clinical trial material to be used in the upcoming ORTHO-R Phase I/II rotator cuff tear repair clinical trial in the US.

Read More:

Tags: , ,

Comments are closed.